FDA grants Fast Track designation to Cardiff Oncology’s onvansertib for KRAS/NRAS‑mutated metastatic colorectal cancer

The U.S. Food and Drug Administration awarded Fast Track status to onvansertib, Cardiff Oncology’s investigational drug, for first‑line treatment of adult patients with KRAS‑ or NRAS‑mutated metastatic colorectal cancer. The designation is based on Phase 2 CRDF‑004 trial data that showed a 72.2% confirmed objective response rate. The news was released before the market opened, and CEO Mani Mohindru discussed the milestone at the UBS Global Biopharma Conference.

The Fast Track designation may accelerate the drug’s development timeline and could increase the company’s valuation, as investors have already driven the share price sharply higher. The FDA’s recognition of an unmet medical need also positions the drug for potential priority review later in the pipeline.

  • 1The FDA granted Fast Track designation to onvansertib for KRAS‑ or NRAS‑mutated metastatic colorectal cancer.
  • 2The Phase 2 CRDF‑004 trial reported a 72.2% confirmed objective response rate for the 30 mg onvansertib regimen.
  • 3CEO Mani Mohindru presented the regulatory milestone at the UBS Global Biopharma Conference.
  • Material 1 reports a pre‑market share rise of 12.82%, while material 2 reports a morning surge of roughly 25%, indicating conflicting figures for the stock move.

Sources